NYSE:MRK
Merck & Co., Inc. (MSD outside of the U.S. and Canada)
- Stock
industry
Drug Manufacturers / Generalexchange
New York Stock Exchangewebsite
www.merck.comipo date
Jun 15, 1946full time employees
67,000currency
USD
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, ...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus
founders
- George W. Merck
investors
Partners | Funding Round | Investor Name | Lead Investor |
---|---|---|---|
— | Post-IPO Equity - Merck | Private Capital Advisors | Yes |
— | Venture Round - Merck | Gavi, the Vaccine Alliance | Yes |
investments
Money Raised | Funding Round | Lead Investor | Announced Date | Organization Name |
---|---|---|---|---|
$23.3M | Venture Round - Prognos Health | — | 04-05-2023 | Prognos Health |
$3.3M | Seed Round - Mamotest | — | 27-03-2023 | Mamotest |
$40M | Series C - Qure AI | — | 30-03-2022 | Qure AI |
$1B | Post-IPO Equity - Seagen | Yes | 14-09-2020 | Seagen |
$3M | Series B - Zapata Computing | — | 28-08-2020 | Zapata Computing |
$14M | Series B - SAB Biotherapeutics | — | 17-07-2020 | SAB Biotherapeutics |
€40M | Series D - Themis Bioscience | — | 18-09-2019 | Themis Bioscience |
— | Seed Round - Mesentech | — | 24-05-2019 | Mesentech |
— | Series B - Clinithink | Yes | 03-03-2019 | Clinithink |
— | Non Equity Assistance - Kytopen | — | 04-02-2019 | Kytopen |
acquisitions
Price | Acquiree Name | Announced Date | Transaction Name |
---|---|---|---|
— | Harpoon Therapeutics | 08-01-2024 | Harpoon Therapeutics acquired by Merck |
$10.8B | Prometheus Biosciences | 16-04-2023 | Prometheus Biosciences acquired by Merck |
$1.4B | Imago BioSciences | 21-11-2022 | Imago BioSciences acquired by Merck |
$11.5B | Acceleron Pharma | 30-09-2021 | Acceleron Pharma acquired by Merck |
$1.9B | Pandion Therapeutics | 25-02-2021 | Pandion Therapeutics acquired by Merck |
$425M | OncoImmune | 23-11-2020 | OncoImmune acquired by Merck |
$2.8B | VelosBio | 05-11-2020 | VelosBio acquired by Merck |
— | Themis Bioscience | 26-05-2020 | Themis Bioscience acquired by Merck |
$2.7B | ArQule | 09-12-2019 | ArQule acquired by Merck |
$576M | Calporta Therapeutics | 13-11-2019 | Calporta Therapeutics acquired by Merck |
num employees
- 10001+
funding rounds
Money Raised | Announced Date | Lead Investors | Transaction Name | Number of Investors |
---|---|---|---|---|
$586K | 25-11-2018 | Private Capital Advisors | Post-IPO Equity - Merck | 1 |
$5M | 21-01-2016 | Gavi, the Vaccine Alliance | Venture Round - Merck | 1 |